Zymeworks Inc reports results for the quarter ended in January 1 - Earnings Summary

Zymeworks

01/11/2024 03:35

* Zymeworks Inc  ZYME.OQ  reported a quarterly adjusted loss
of 39
cents​​ per share for the quarter ended January 1, higher than
the same quarter last year, when the company reported EPS of -41
cents.  The mean expectation of seven analysts for the quarter
was for a loss of 40 cents per share. Wall Street expected
results to range from -75 cents to -14 cents per share.
    * Revenue fell 3.1% to $16.00 million from a year ago;
analysts
expected $15.30 million. 
    * Zymeworks Inc's reported EPS for the quarter was a loss
of 39
cents​.
    * The company reported a quarterly loss of $29.85 million.
    * Zymeworks Inc shares had risen by 10.5% this quarter and
gained 33.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 14.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Zymeworks Inc is
14.00 
This summary was machine generated from LSEG data November 1 at
03:35 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.40          -0.39          Beat
 Jun. 30 2024      -0.32          -0.27          Beat
 Mar. 31 2024      -0.29          -0.42          Missed
 Dec. 31 2023      -0.43          -0.20          Beat